Management of Challenging Cases in Myositis

In Sum

This session was packed with high yield clinical pearls and management strategies for antisynthetase syndrome, IMNM and dermatomyositis, with an eye toward promising new therapeutics, such as CAR T cell therapy and novel biologics like brepocitinib. These advances offer patients hope for meaningful clinical improvements and ultimately, durable remission.

Michael Cammarata, MD, RhMSUS, is an assistant professor of medicine at the Johns Hopkins University School of Medicine in Baltimore.

References

1. Aggarwal R, Cassidy E, Fertig N, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014;73(1):227–232.
2. Müller F, Boeltz S, Knitza J, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401(10379):815–818.
3. Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: A case series. Arthritis Care Res (Hoboken). 2010;62(9):1328–1334.
4. Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015;373(17):1680–1682.
5. Allenbach Y, Mammen AL, Benveniste O, Stenzel W; Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 Oct 2016. Neuromuscul Disord. 2018;28(1):87–99.
6. Pinard J, Femia AN, Roman M, et al. Systemic treatment for clinically amyopathic dermatomyositis at 4 tertiary care centers. JAMA Dermatol. 2019;155(4):494–496.
7. Femia AN, Eastham AB, Lam C, et al. Intravenous immunoglobulin for refractory cutaneous dermatomyositis: A retrospective analysis from an academic medical center. J Am Acad Dermatol. 2013;69(4):654–657.
8. Danieli MG, Gambini S, Pettinari L, et al. Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmun Rev. 2014;13(10):1048–1054.
9. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143(6):763–767.
10. Huard C, Gullà SV, Bennett DV, et al. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis. Br J Dermatol. 2017;176(5):1224–1230. 
11. Shaw KS, Hashemi KB, Castillo RL, et al. Anifrolumab in recalcitrant cutaneous dermatomyositis: A multicenter retrospective cohort study. J Am Acad Dermatol. 2024;91(6):1217–1219.